Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs
OAKLAND, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- Via Nova Therapeutics announced today that it has closed its Series A financing and raised $20 million from Aditum Bio to advance the development of four preclinical antiviral pro... Biopharmaceuticals, Venture Capital Via Nova Therapeutics, influenza, adenovirus, rhinovirus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2021 Category: Pharmaceuticals Source Type: news

BREAKING GOOD NEWS: These four herbal extracts reduce viral load and block SARS-CoV-2, influenza, adenovirus
(Natural News) A new study investigates the antiviral activity of four plant extracts. Among the plants studied are: green tea (Camellia sinensis), pomegranate juice (Punica granatum), black choke berry juice (Aronia melanocarpa), and elderberry syrup (Sambucus nigra). These medicinal plant extracts were effective in vitro for stopping viral attachment, reducing viral load, and stopping the... (Source: NaturalNews.com)
Source: NaturalNews.com - September 2, 2021 Category: Consumer Health News Source Type: news

Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time. “We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scien...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Mayo Clinic Q & amp;A podcast: How Mayo hopes to slam the door when COVID-19 comes knocking
The COVID-19 pandemic has brought public awareness to vaccines and how vaccines work. A vaccine is any agent that causes the immune system to remember a specific disease-causing entity, thereby preventing future infections. In the case of COVID-19, that's a coronavirus. At Mayo Clinic, decades of research have led to development of a new vaccine platform — a single-cycle adenovirus nasal vaccine — that is now being tested in a phase 1 clinical trial for COVID-19.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 9, 2021 Category: Databases & Libraries Source Type: news

Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
(University of Cincinnati) Researchers at the University of Cincinnati College of Medicine have developed a computerized decision analytic model to compare projected outcomes of three vaccine strategies: a patient opts for a messenger RNA vaccine, a patient decides to get an adenovirus vector vaccine or the patient simply forgoes a vaccine altogether. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 20, 2021 Category: Infectious Diseases Source Type: news

The virus trap
(Technical University of Munich (TUM)) To date, there are no effective antidotes against most virus infections. An interdisciplinary research team at the Technical University of Munich (TUM) has now developed a new approach: they engulf and neutralize viruses with nano-capsules tailored from genetic material using the DNA origami method. The strategy has already been tested against hepatitis and adeno-associated viruses in cell cultures. It may also prove successful against corona viruses. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

I Got a J & J Vaccine. Should I Get a Booster Shot as Delta Spreads?
Welcome to COVID Questions, TIME’s advice column. We’re trying to make living through the pandemic a little easier, with expert-backed answers to your toughest coronavirus-related dilemmas. While we can’t and don’t offer medical advice—those questions should go to your doctor—we hope this column will help you sort through this stressful and confusing time. Got a question? Write to us at covidquestions@time.com. Today, N.C. in Washington, D.C., asks: I got a Johnson & Johnson vaccine. With the Delta variant spreading, I’ve heard that some people in my position are also getting s...
Source: TIME: Health - July 8, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID Questions COVID-19 Source Type: news

I Got a J & J Vaccine. Should I Get a Booster Shot as Delta Spreads?
Welcome to COVID Questions, TIME’s advice column. We’re trying to make living through the pandemic a little easier, with expert-backed answers to your toughest coronavirus-related dilemmas. While we can’t and don’t offer medical advice—those questions should go to your doctor—we hope this column will help you sort through this stressful and confusing time. Got a question? Write to us at covidquestions@time.com. Today, N.C. in Washington, D.C., asks: I got a Johnson & Johnson vaccine. With the Delta variant spreading, I’ve heard that some people in my position are also getting s...
Source: TIME: Science - July 8, 2021 Category: Science Authors: Jamie Ducharme Tags: Uncategorized COVID Questions COVID-19 Source Type: news

New vaccine platform invented by Mayo enters COVID-19 clinical trial
A Mayo Clinic lab member is purifying an adenovirus vector for preclinical testing. A novel single-cycle adenovirus vaccine platform developed by Mayo Clinic will be used to target multiple infectious diseases and cancer indications, beginning with a phase 1 clinical study using the platform as a vaccine for COVID-19. Developed to enhance the expression of target antigens, the single-cycle adenovirus platform is under investigation for its ability to amplify immune responses. In contrast to replication-defective… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 6, 2021 Category: Databases & Libraries Source Type: news

Improving Cancer Immunotherapy with Anti-Cancer Adenoviruses
Researchers use a mesenchymal stromal cell-based vector to deliver multiple viruses simultaneously to improve CAR-T cell anti-tumor activity. (Source: The Scientist)
Source: The Scientist - June 25, 2021 Category: Science Tags: The Marketplace Source Type: news

Microscopy deep learning predicts viral infections
(University of Zurich) When viruses infect cells, changes in the cell nucleus occur, and these can be observed through fluorescence microscopy. Using fluorescence images from live cells, researchers at the University of Zurich have trained an artificial neural network to reliably recognize cells that are infected by adenoviruses or herpes viruses. The procedure also identifies severe acute infections at an early stage. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 21, 2021 Category: Infectious Diseases Source Type: news

ONCOS-102 Vaccine Showing Impressive Results for Mesothelioma
The novel immunotherapy vaccine ONCOS-102 may become the answer for the large percentage of mesothelioma cancer patients who fail to respond to a recently approved checkpoint inhibitor combination of treatment. ONCOS-102, a genetically modified oncolytic adenovirus, showed an overall survival rate of between 21.9 and 25 months in a randomized phase II clinical trial when combined with standard chemotherapy in a first-line setting. By comparison, patients in the trial receiving only standard chemotherapy had a median survival of just 13.5 months. The vaccine is the lead product of Targovax, a small Scandinavian bio...
Source: Asbestos and Mesothelioma News - June 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Are There Clinically Meaningful Differences Between anti-COVID-19 Vaccines?
A health worker prepares to administer the COVID-19 vaccine to her colleague at a hospital in Mogadishu, Somalia.In a video message on May 24 to the World Health Assembly , the decision-making body of UN agency WHO, UN Secretary-General Antonio Guterres warned against the dangers of “a two-speed global response”, a concern he has frequently expressed. “Sadly, unless we act now, we face a situation in which rich countries vaccinate the majority of their people and open their economies, while the virus continues to cause deep suffering by circling and mutating in the poorest countries,” he said. Credi...
Source: IPS Inter Press Service - Health - May 28, 2021 Category: International Medicine & Public Health Authors: Sunil J. Wimalawansa Tags: Aid Development & Aid Featured Global Headlines Health Humanitarian Emergencies IPS UN: Inside the Glasshouse Poverty & SDGs TerraViva United Nations Source Type: news

Possible Cause Found for Rare Blood Clots Tied to Some COVID-19 Vaccines
THURSDAY, May 27, 2021 -- The cause of rare blood clots in some people who have received the AstraZeneca and Johnson& Johnson COVID-19 vaccines has been found, researchers report. The vaccines use adenovirus vectors to transfer the vaccine's... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 27, 2021 Category: Pharmaceuticals Source Type: news

German scientists say they can help improve Covid vaccines to prevent blood clots
AstraZeneca and Johnson& Johnson jabs have caused rare blood clots but scientists say they can be redesigned to avoid problemCoronavirus – latest updatesSee all our coronavirus coverageA team of German scientists believe that they have worked out whysome people given the AstraZeneca andJohnson& Johnson vaccines against Covid-19 develop blood clots – and claim they can tell the manufacturers how to improve the vaccine to avoid it.The key is in the adenovirus – the common cold virus that is used to deliver the spike protein of the coronavirus into the body, say Rolf Marschalek, a professor at Goethe...
Source: Guardian Unlimited Science - May 26, 2021 Category: Science Authors: Sarah Boseley Health editor Tags: Coronavirus UK news AstraZeneca Science Pharmaceuticals industry Source Type: news

Scientists claim to have solved Covid vaccine blood-clot puzzle
German researchers say side effect caused by adenovirus vector and can be fixed (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 26, 2021 Category: Pharmaceuticals Source Type: news

A Blind Patient Regained Partial Sight in a Breakthrough Study, Offering Hope to Millions
The darkness descends slowly for people with retinitis pigmentosa (RP), a degenerative eye disease that affects 2 million people worldwide. The condition is typically diagnosed in childhood or adolescence, but it can take until middle age before a person’s vision has deteriorated severely enough that they are fully or effectively blind. When the lights finally do go out, however, they stay out. Or that’s the way things used to be. In a breakthrough study published today in Nature Medicine, investigators report a relatively simple yet remarkably effective way to restore partial vision to RP patients—one th...
Source: TIME: Science - May 24, 2021 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized embargoed study Innovation Source Type: news

A Blind Patient Regained Partial Sight in a Breakthrough Study, Offering Hope to Millions
The darkness descends slowly for people with retinitis pigmentosa (RP), a degenerative eye disease that affects 2 million people worldwide. The condition is typically diagnosed in childhood or adolescence, but it can take until middle age before a person’s vision has deteriorated severely enough that they are fully or effectively blind. When the lights finally do go out, however, they stay out. Or that’s the way things used to be. In a breakthrough study published today in Nature Medicine, investigators report a relatively simple yet remarkably effective way to restore partial vision to RP patients—one th...
Source: TIME: Health - May 24, 2021 Category: Consumer Health News Authors: Jeffrey Kluger Tags: Uncategorized embargoed study Innovation Source Type: news

Two Voyager Therapeutics executives step down amid pivot
Voyager Therapeutics (Nasdaq: VYGR) is losing two executives this spring as the gene therapy company shifts its focus to engineering capsids for adeno-associated viruses (AAVs) that deliver gene-altering treatments. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 20, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news

Johnson & Johnson Joins World Health Organization in Efforts to Prevent Spread of Ebola in West Africa
Discussions are ongoing with the U.S. Food and Drug Administration regarding the approval of the vaccine regimen in the U.S. WHO Prequalification is often a prerequisite for national registrations of new vaccines and medicines in developing countries. Johnson & Johnson now looks forward to collaborating with the WHO’s African Vaccine Regulatory Forum (AVAREF) to progress national registrations of the Company’s Ebola vaccine regimen. The Company’s Ebola vaccine regimen is designed to be used proactively to induce immunity against Ebola virus disease in adults and children. Johnson & Johnson’s...
Source: Johnson and Johnson - May 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Novavax ’s COVID-19 Vaccine Was Shown to be 51% Efficacious in South Africa, Where More Infectious Variants Are Spreading
In a study published in the New England Journal of Medicine, researchers from the Maryland-based biotech firm Novavax report that the company’s COVID-19 vaccine is 51% efficacious in protecting people from disease. The results come from a Phase 2 study of the two-dose vaccine, which uses a different technology than the three COVID-19 shots currently authorized by the U.S. Food and Drug Administration. Currently authorized shots from Pfizer-BioNTech and Moderna both use an mRNA-based technology, while Johnson & Johnson-Janssen relies on an adenovirus to deliver SARS-CoV-2 genes to the body—both approaches wo...
Source: TIME: Health - May 6, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

The Most Important Thing Rich Countries Can Do to Help India Fight COVID-19
The Biden Administration is debating whether COVID-19 vaccine patents should be temporarily waived, given the devastating humanitarian crisis unfolding in India from the virus. There are two key factors that should drive the Biden team to agree to do so: first, there is strong precedent on waiving patents in the context of public health emergencies; second, the real-world effectiveness of most COVID-19 vaccines against symptomatic disease and transmission can temper the disaster. The Biden Administration will be making its decision on lifting some patent restrictions as early as May 5. India faces a catastrophe, with ove...
Source: TIME: Health - May 5, 2021 Category: Consumer Health News Authors: Dr. Monica Gandhi Tags: Uncategorized COVID-19 India Source Type: news

Brazilian scientists claim they've discovered live, replicating adenoviruses in Russia’s covid vaccines
(Natural News) Brazilian scientists discovered a serious issue with Russia’s Sputnik V covid vaccine. This serious issue could lead to a new public health crisis, which is why Brazilian regulators have banned the import of this vaccine. The vaccine in question was developed by Russia’s Gamaleya Institute. Like the AstraZeneca and the Johnson & Johnson... (Source: NaturalNews.com)
Source: NaturalNews.com - April 30, 2021 Category: Consumer Health News Source Type: news

Moderna Is Testing a New Version of Its COVID-19 Vaccine That Wouldn ’t Require Ultra-Cold Storage
As safety concerns over COVID-19 vaccines from AstraZeneca and Johnson&Johnson–Janssen have led to disruptions in the inoculation efforts of numerous countries relying on those shots, companies like Moderna are attempting to fill the resulting gaps. The Massachusetts-based biotech company announced on April 29 that it is investing billions to boost manufacturing facilities in Switzerland, Spain and the U.S., building enough capacity to produce up to 3 billion doses of its mRNA-based vaccine through 2022. The company’s vaccine technology differs from that of AstraZeneca and J&J, which both use an adenovi...
Source: TIME: Health - April 29, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Single-Dose Ad26.COV2.S Effective Against COVID-19
FRIDAY, April 23, 2021 -- A single dose of human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 spike protein (Ad26.COV2.S) protects against moderate- to severe-critical and severe-critical COVID-19,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

Australia set to host clinical trial of genetically modified Covid nasal spray vaccine
Australian company applies for permission to conduct trial of men and women aged 18 to 55Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.Avance Clinical, an Australian contract research organisation, hasapplied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 23, 2021 Category: Science Authors: Paul Karp Tags: Vaccines and immunisation Coronavirus Australia news Science Health Source Type: news

J & J Refutes Idea That COVID-19 Vaccine's Design Linked to Clots J & J Refutes Idea That COVID-19 Vaccine's Design Linked to Clots
Scientists at J&J refuted an assertion in a medical journal that the adenovirus-based design of their COVID vaccine may explain why both J&J and AZ vaccines have been linked to very rare brain blood clots.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 19, 2021 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

J&J’s Covid setback risks damaging its vaccine programme
Rebuilding trust may take time after blood clot concerns with adenovirus-based jab (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 19, 2021 Category: Pharmaceuticals Source Type: news

Spike proteins in Pfizer, Moderna Covid-19 vaccines linked to deadly blood clots, brain inflammation and heart attacks
(Natural News) The media is giving considerable airtime to the deadly blood clot issue with Wuhan coronavirus (Covid-19) injections from AstraZeneca and Johnson & Johnson (J&J), both of which are manufactured using adenovirus technology. New evidence, though, shows that the messenger RNA (mRNA) injections from Pfizer-BioNTech and Moderna can cause the same issues and more.... (Source: NaturalNews.com)
Source: NaturalNews.com - April 16, 2021 Category: Consumer Health News Source Type: news

What's different about Johnson & Johnson's vaccine that might explain its blood clot risk?
Why might some COVID-19 vaccines pose a small risk of blood clots while others don't? Scientists suspect it's related to their use of adenoviruses. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - April 15, 2021 Category: Science Authors: Karen Kaplan Source Type: news

What's different about Johnson & Johnson's vaccine that might explain its blood clot risk?
Why might some COVID-19 vaccines pose a small risk of blood clots while others don't? Scientists suspect it's related to their use of adenoviruses. (Source: L.A. Times - Health)
Source: L.A. Times - Health - April 15, 2021 Category: Consumer Health News Authors: Karen Kaplan Source Type: news

How Some COVID-19 Vaccines Could Cause Rare Blood Clots How Some COVID-19 Vaccines Could Cause Rare Blood Clots
Regulatory agencies in the US and around the world are scrambling to determine the risk of potentially lethal but rare blood clots linked to adenovirus vaccines.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 14, 2021 Category: Cardiology Tags: Infectious Diseases News Source Type: news

FDA and CDC Recommend Pausing COVID-19 Vaccination With J & J-Janssen Shot While They Investigate Blood Clot Risks
The U.S. Food and Drug Administration and Centers for Disease Control and Prevention are recommending that vaccinations with the Johnson & Johnson/Janssen COVID-19 vaccine be temporarily halted while the agencies review reports of blood clots among vaccinated people. On April 13, the two government agencies issued a joint statement announcing a recommended pause as federal regulators review six cases of blood clots reported six to 13 days after the people received the single-dose vaccine. “Until that [review] process is complete, we are recommending a pause in the use of this vaccine out of an abundance of cautio...
Source: TIME: Health - April 13, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Two New Studies Point to How AstraZeneca ’s COVID-19 Vaccine Is Linked to Blood Clots
In two papers published in the New England Journal of Medicine (NEJM), researchers in Europe provide the most detailed explanation yet for what is behind the clotting side effects reported among people getting vaccinated with the AstraZeneca COVID-19 shot. In both papers, researchers found that people getting the vaccine had higher levels of antibodies directed against a cluster of immune-related cells that the body might form in response to the vaccine. These clusters include platelets, which help blood to clot when you get cut or injured, and the antibodies stick to the platelet-complex and form dangerous clots that can ...
Source: TIME: Health - April 9, 2021 Category: Consumer Health News Tags: Uncategorized COVID-19 Source Type: news

Science Saturday: Vaccine efforts move forward at Mayo Clinic
Humanity has taken on infectious agents, such as the virus that causes smallpox, and won. But cheer quietly. Smallpox eradication took 200 years, and it's just one of the many diseases out there. But hey, researchers are nothing if not persistent, right? A Mayo Clinic lab member is purifying an adenovirus vector for preclinical testing. That's [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 27, 2021 Category: Databases & Libraries Source Type: news

AstraZeneca ’s U.S. Study May Answer Some of the Lingering Questions About Its Vaccine
This study puts to bed any doubts that this isn’t a highly effective vaccine against COVID-19 disease and COVID-19 symptoms,” says Mene Pangalos, executive vice president for biopharmaceuticals research and development at AstraZeneca. AstraZeneca’s vaccine is based on technology developed by scientists at Oxford University’s Jenner Institute, and involves using a chimpanzee adenovirus modified so it cannot cause the cold infection it normally does. The chimp virus acts as a vehicle to deliver genes into the body, where it encodes the SARS-CoV-2 spike protein; cells then process the protein so the im...
Source: TIME: Health - March 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Your coronavirus vaccine guide: Covishield vs Covaxin
Oxford-AstraZeneca made Covishield is based on the viral vector platform. The vaccine is made by genetically engineering adenovirus that normally infects chimpanzees. It uses double-stranded DNA. Bharat Biotech made Covaxin is based on an inactivated form of the coronavirus. (Source: The Economic Times)
Source: The Economic Times - March 2, 2021 Category: Consumer Health News Source Type: news

Study: Which Mesothelioma Patients Will Immunotherapy Benefit?
This study also is designed to better understand the biological mechanisms affecting the immune system. The goal is to use both the cellular organization and molecular pathways to develop a test that can predict the response to the checkpoint inhibitor drugs. Upon completion, a clinical trial would follow, in which treatment would depend on the results of the individual’s test. “Within the next year or two, we’ll have a good idea of whether these components are working,” Burt said. The post Study: Which Mesothelioma Patients Will Immunotherapy Benefit? appeared first on Mesothelioma Center - Vital S...
Source: Asbestos and Mesothelioma News - February 23, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

FDA Fast-Tracks Mesothelioma Vaccine Development
The U.S. Food and Drug Administration has granted Fast-Track Designation this week to ONCOS-102, an immunotherapy vaccine that targets malignant mesothelioma and other hard-to-treat tumors. This designation is expected to expedite the regulatory approval process. The vaccine’s developer, Targovax, a small biotech company that focuses on oncolytic viruses, sees this as an early endorsement from the FDA. “Yes, this opens the door for us,” Dr. Magnus Jaderberg, chief medical officer of Targovax, told The Mesothelioma Center at Asbestos.com. “It validates what the FDA believes is a potentially promising...
Source: Asbestos and Mesothelioma News - February 19, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Optimizing Adeno-Associated Virus (AAV) Manufacturing
Scientists wield nature ’s power to optimize adeno-associated virus (AAV) production and maximize gene therapy safety. (Source: The Scientist)
Source: The Scientist - February 16, 2021 Category: Science Tags: Research Products Blog Source Type: news

Zika vaccine candidate shows promise in phase I trial
(American College of Physicians) The Zika virus candidate, Ad26.ZIKV.001, a replication-incompetent human adenovirus serotype 26 (ad26) vector showed promising safety and immunogenicity in a phase I clinical trial. Researchers say the vaccine warrants further development should the need reemerge. The findings are published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 15, 2021 Category: Infectious Diseases Source Type: news

A new vision for adeno-associated virus delivered gene therapies
An international collaboration of leading groups in gene therapy and vision science have developed an adeno-associated virus (AAV) genome-coupled immunomodulation strategy that helps cloak the AAV virus from unwanted immune responses and offers important insights into ocular inflammation. The research led by Harvard University, Harvard Medical School and including the University of Bristol is published in Science Translational Medicine. (Source: University of Bristol news)
Source: University of Bristol news - February 11, 2021 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Translational Health Sciences, Faculty of Life Sciences, Faculty of Life Sciences, School of Cellular and Molecular Medicine; Press Release Source Type: news

Do Vaccines Stop the Spread of COVID-19? What You Need to Know
The way most people think of vaccines is pretty simple: you get vaccinated, and your immune system is primed and trained to fight off the invisible intruder in question, be it virus or bacteria. If you’re protected, you can’t be infected, and if you’re not infected, then you can’t spread it to anyone else. And that’s true most of the time. But not all vaccines work that way, and it’s not actually what the two COVID-19 vaccines authorized by the U.S. Food and Drug Administration—made by Moderna and Pfizer-BioNtech—are designed to do. Their effectiveness is measured by how well...
Source: TIME: Health - February 11, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

High Efficacy Reported for Sputnik V COVID-19 Vaccine
THURSDAY, Feb. 4, 2021 -- A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), has 91.6 percent efficacy against COVID-19, according to a study published online Feb. 2 in The Lancet. Denis Y. Logunov, D.Sc., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 4, 2021 Category: Pharmaceuticals Source Type: news

Intranasal influenza vaccine spurs strong immune response in Phase 1 study
(NIH/National Institute of Allergy and Infectious Diseases) An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in theJournal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 3, 2021 Category: Infectious Diseases Source Type: news

Lancet peer-reviewed study endorses Russia's Sputnik V Covid-19 vaccine
Sputnik V uses two adenoviruses, AD 5 and AD 26, that target the spike protein of the SARS Cov2 virus. Companies such as AstraZeneca, Johnson& Johnson and CanSino are using one of these 2 vectors for their vaccines. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2021 Category: Pharmaceuticals Source Type: news

The Lancet: Study reports preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine trial
(The Lancet) An interim analysis of data from the phase 3 trial of the COVID-19 vaccine from Russia (Gam-COVID-Vac) suggests that a two-dose regimen of the adenovirus-based vaccine offers 91.6% efficacy against symptomatic COVID-19. The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three-quarters of whom received the vaccine and one quarter received a placebo. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 2, 2021 Category: Infectious Diseases Source Type: news

AAVCOVID single-dose, room temperature-stable COVID-19 vaccine supported by new funding
(Massachusetts Eye and Ear Infirmary) The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill& Melinda Gates Foundation. The grant will aid the effort to bring further preclinical validation to the AAVCOVID platform and its single-dose, room temperature stable vaccine candidates. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 29, 2021 Category: Infectious Diseases Source Type: news

MAIT cell activation augments adenovirus vector vaccine immunogenicity
Mucosal-associated invariant T (MAIT) cells are innate sensors of viruses and can augment early immune responses and contribute to protection. We hypothesized that MAIT cells may have inherent adjuvant activity in vaccine platforms that use replication-incompetent adenovirus vectors. In mice and humans, ChAdOx1 (chimpanzee adenovirus Ox1) immunization robustly activated MAIT cells. Activation required plasmacytoid dendritic cell (pDC)–derived interferon (IFN)–α and monocyte-derived interleukin-18. IFN-α–induced, monocyte-derived tumor necrosis factor was also identified as a key secondary sign...
Source: ScienceNOW - January 28, 2021 Category: Science Authors: Provine, N. M., Amini, A., Garner, L. C., Spencer, A. J., Dold, C., Hutchings, C., Silva Reyes, L., FitzPatrick, M. E. B., Chinnakannan, S., Oguti, B., Raymond, M., Ulaszewska, M., Troise, F., Sharpe, H., Morgan, S. B., Hinks, T. S. C., Lambe, T., Capone, Tags: Immunology, Microbiology reports Source Type: news

Biodistribution of AAV gene transfer vectors in nonhuman primate
(Mary Ann Liebert, Inc./Genetic Engineering News) The biodistribution of adeno-associated virus (AAV) gene transfer vectors can be measured in nonhuman primates using a new method. The method quantifies whole-body and organ-specific AAV capsids from 1 to 72 hours after administration (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 15, 2021 Category: International Medicine & Public Health Source Type: news